Most Read Articles
Jairia Dela Cruz, 6 days ago
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Gentamicin exposure in the NICU does not affect hearing screen results

31 Dec 2018
The Kangaroo Mother Care (KMC) idea, which originated amid grinding poverty, may be a cheaper and better option than incubators in saving premature babies.

Gentamicin treatment in infants, regardless of dosing or duration, does not affect the risk of failing a hearing screen at the time of discharge from the neonatal intensive care unit (NICU), a recent study has found.

The study included 84,808 infants who received gentamicin in the first 120 days of life, of whom 15 percent (n=12,593) were born very low birth weight (VLBW). Participants received an average daily dose of 3.8 mg/kg/day. The cumulative dose received and median duration of exposure was 12.1 mg/kg and 3 days, respectively.

The median cumulative daily dose received was significantly higher in those who failed than in those who passed (15.26 vs 12.08 mg/kg), though there was no difference in the highest daily dose administered (3.98 vs 3.96 mg/kg; p=0.21).

Of the participants, only 3.8 percent (n=3,238) failed the hearing screen. Multivariable adjusted logistic regression analysis showed that gentamicin exposure, measured as the average daily dose (odds ratio [OR], 1.01; 95 percent CI, 0.98–1.05; p=0.46), had no significant impact on the risk of failing the hearing screen.

The findings held true when exposure was measured as cumulative dose (OR, 1.00; 1.00–1.00; p=0.07), highest daily dose (OR, 0.99–1.05; p=0.20) and duration of exposure (OR, 1.01; 1.00–1.02; p=0.10).

A subgroup analysis on VLBW similarly showed that gentamicin exposure had generally no impact on hearing screen results (average daily dose: OR, 1.02; 0.97–1.07; p=0.54; highest daily dose: HR, 1.03; 0.99–1.07; p=0.13; duration of exposure: OR, 1.01; 0.99–1.02; p=0.26), except for when measured cumulative dose, though the magnitude of effect was minimal (OR, 1.00; 1.00–1.01; p=0.03).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
The potassium-competitive acid blocker vonoprazan demonstrates superior efficacy in the treatment of patients with erosive oesophagitis compared with the proton pump inhibitor lansoprazole, with the results of a small trial showing that the former more rapidly provides complete sustained heartburn relief during the first week of therapy.
01 Mar 2016
Bathing with 2% chlorhexidine gluconate-medicated washcloth is cost-effective for the prevention of central line-associated bloodstream infection (CLABSI), based on a systematic review and meta-analysis of four studies.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.